ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation

This study identified the activation of Sirt3 played an important role in increasing sensitivity of ovarian cancer cells to cisplatin induced by ABT737. Furthermore, Sirt3 might represent a potential therapeutic target for ovarian cancer.
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

ConclusionsThese data support further investigation of A1mcMMAF in combination with platinum-based chemotherapy in ovarian and other cancer treatments.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Publication date: August 2019Source: European Journal of Surgical Oncology, Volume 45, Issue 8Author(s): M. Timmermans, G.S. Sonke, B.F.M. Slangen, A. Baalbergen, R.L.M. Bekkers, G. Fons, C.G. Gerestein, A.J. Kruse, E.M. Roes, P.L.M. Zusterzeel, K.K. Van de Vijver, R.F.P.M. Kruitwagen, M.A. van der AaAbstractIntroductionThe care for patients with epithelial ovarian cancer(EOC) is organised in eight different geographical regions in the Netherlands. This situation allows us to study differences in practice patterns and outcomes between geographical regions for patients with FIGO stage IIIC and IV.MethodsWe identified all EO...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Authors: Ishikura N, Yorozu K, Kurasawa M, Yanagisawa M, Sugimoto M, Yamamoto K Abstract Although bevacizumab maintenance following bevacizumab in combination with chemotherapy has demonstrated significant prolongation of progression-free survival in clinical studies in patients with ovarian cancer, the majority of the cancer cases in the study were of the serous histotype; therefore, data regarding clear cell carcinoma is limited. Furthermore, the efficacy of bevacizumab beyond progression has not yet been demonstrated in ovarian cancer. A xenograft model using the human ovarian clear cell carcinoma cell line RMG-...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Inhibition of ubiquitin‑specific protease 14 promotes connexin 32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells. Oncol Rep. 2019 Jul 15;: Authors: Luo H, Wang X, Ge H, Zheng N, Peng F, Fu Y, Tao L, Wang Q Abstract Although cisplatin is one of the most accepted therapies for ovarian cancer, recurrence and drug resistance remain problematic. Both the ubiquitin‑proteasome system (UPS) and connexin (Cx) are closely related to tumor progression. However, the role of ubiquitin‑specific protease 14 (USP14) and Cx in mediating drug resistance rem...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Deng M, Sun J, Xie S, Zhen H, Wang Y, Zhong A, Zhang H, Lu R, Guo L Abstract Chemotherapy is widely used for the treatment of ovarian cancer. Since chemotherapy resistance is the major cause of poor prognosis in patients with ovarian cancer, it is important to identify new methods to improve the efficacy of chemotherapy. Minichromosome maintenance complex component 2 (MCM2), which serves an essential role in DNA replication, has been recently identified as a novel proliferation marker with prognostic implications in multiple types of cancer. However, the role of MCM2 in ovarian cancer and its underlying mo...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
This study revealed the possible occurrence and recurrence risk factors of ovarian endometriosis malignancy using univariate and multivariate statistics analyses. What are the implications of these findings for clinical practice and/or further research? A clinical retrospective study with a longer follow-up period is suggested for assessing the occurrence and recurrence risk factors for ovarian endometriosis malignancies. PMID: 31307261 [PubMed - as supplied by publisher]
Source: Journal of Obstetrics and Gynaecology - Category: OBGYN Tags: J Obstet Gynaecol Source Type: research
ConclusionSimultaneous resection of hepatic and peritoneal metastases seems to provide a survival benefit for selected patients and is associated with acceptable morbidity and mortality rates. Knowledge of patients and operative factors linked to morbidity will help to provide a strict selection process and a safer surgical procedure.
Source: Journal of Visceral Surgery - Category: Surgery Source Type: research
ConclusionsPathological evaluation provides a more accurate and objective assessment of extent and distribution of peritoneal disease. Lymph node involvement in relation of peritoneal disease is common. The morphological presentation of PM in ovarian cancer and mucinous appendiceal tumors merits evaluation of more extensive resections in these patients. Standardized methods of synoptic reporting of CRS specimens could help capture vital prognostic information that may in future influence how these patients are treated.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionsUnlike ovarian cancer, less than half of the patients undergoing NACT for endometrial cancer underwent IDS, none had a complete response, and 41% had disease progression during NACT. However, endometrial cancer patients who underwent IDS had a high rate of optimal cytoreduction. Both response to NACT and IDS were associated with improved survival.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
GlaxoSmithKline said on Monday a late-stage study testing its initial maintenance therapy, Zejula, in patients with ovarian cancer who have undergone platinum-based chemotherapy showed positive results.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Ovarian Cancer | Ovaries | Study